Study for Evaluation of GM102 Anti-tumoral Activity in Colorectal Cancers
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new
compound (monoclonal antibody), administered alone or in combination with chemotherapy in
patients with locally advanced or metastatic colorectal cancer. The primary objective of the
study is to evaluate the antitumor activity of GM102 single agent and in combination with
trifluridine/tipiracil.